Document is current
Any future updates will be listed below
-
Authors
Greiner, S. M. https://orcid.org/0000-0002-1378-2975
Mauermann, J.
Lutz, M. S.
Hagelstein, I.
Hartkopf, A. D.
Zekri, L.
Jung, G.
Salih, H. R.
Märklin, M.
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (MA 9302/2-1)
Deutsche Krebshilfe (70114180, 70113496, 70115833)
Bundesministerium für Bildung und Forschung (01EJ2403A)
Carl-Zeiss-Stiftung (P2024-02-012)
Universitätsklinikum Tübingen
- License Information
-
More Information
Article History
Received: 27 March 2025
Accepted: 28 June 2025
First Online: 24 July 2025
Declarations
:
: The study was approved by the IRB (Ethics Committee of the Medical Faculty of the Eberhard Karls Universitaet Tuebingen) at the University Hospital Tuebingen and was conducted in accordance with the Declaration of Helsinki; reference number 13/2007 V. Human material was collected after written informed consent was obtained.
: GJ, HRS and LZ are listed as inventors on the patent application “Antibodies targeting, and other modulators of, the CD276 antigen, and uses thereof,” EP3822288A1, applicant is German Cancer Research Center, Heidelberg, and Medical Faculty University of Tübingen, Germany.
